Research programme: selective estrogen receptor modulators - Bionovo

Drug Profile

Research programme: selective estrogen receptor modulators - Bionovo

Alternative Names: BN-AA-003-NY; BN-AM-008-XG; BN-AO-014; BN-CB-045; BN-DF-037; BN-ES-022; BN-EU-036; BN-GU-005-DHP; BN-OB-026; BN-PC-049-BK; BN-RP-006-OHA

Latest Information Update: 12 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bionovo
  • Class
  • Mechanism of Action Estrogen receptor beta agonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Metabolic syndrome
  • No development reported Breast cancer; Colorectal cancer; Female sexual dysfunction; Joint disorders; Menopausal syndrome; Obesity; Postmenopausal osteoporosis

Most Recent Events

  • 12 Mar 2012 No development reported - Preclinical for Breast cancer in USA (unspecified route)
  • 12 Mar 2012 No development reported - Preclinical for Colorectal cancer in USA (unspecified route)
  • 12 Mar 2012 No development reported - Preclinical for Female sexual dysfunction in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top